Table 2.
Glycemic, inflammatory, lipid, and body composition parameters
| Salsalate
|
Placebo
|
P value for comparison of change between groups | |||||
|---|---|---|---|---|---|---|---|
| Baseline | 1 month | % change from baseline | Baseline | 1 month | % change from baseline | ||
| Glucose metabolism | |||||||
| Glucose (mmol/l) | 5.0 ± 0.2 | 4.6 ± 0.1* | −8 | 4.8 ± 0.1 | 5.1 ± 0.1* | +5 | <0.002 |
| Glycated albumin (%) | 12.4 ± 0.4 | 10.3 ± 0.3* | −17 | 12.5 ± 0.3 | 12.4 ± 0.4 | −1 | <0.0003 |
| Glucose AUC (mmol · min−1 · l−1) | 905 ± 42 | 776 ± 50 | −14 | 801 ± 40 | 840 ± 42 | +6 | <0.004 |
| C-peptide (nmol/l) | 1.6 ± 0.2 | 1.1 ± 0.2* | −24 | 1.5 ± 0.2 | 1.5 ± 0.2 | +5 | <0.01 |
| Insulin (pmol/l) | 112 ± 21 | 124 ± 18 | +27 | 97 ± 12 | 98 ± 10 | +6 | 0.5 |
| HOMA IR C-peptide | 1.1 ± 0.2 | 0.7 ± 0.1* | −29 | 1.0 ± 0.1 | 1.0 ± 0.1 | +10 | <0.004 |
| Inflammatory parameters | |||||||
| Adiponectin (mg/l) | 10.6 ± 1.7 | 16.2 ± 2.7* | +56 | 10.8 ± 1.5 | 10.5 ± 1.5 | −1 | <0.003 |
| FFA (mEq/l) | 0.46 ± 0.08 | 0.25 ± 0.05 | −14† | 0.42 ± 0.06 | 0.37 ± 0.08 | −14 | 0.9 |
| CRP (nmol/l) | 48.2 ± 10.5 | 30.2 ± 7.4* | −34 | 45.4 ± 8.4 | 42.7 ± 9.6 | −8 | 0.2 |
| Lipid parameters | |||||||
| LDL (mmol/l) | 2.9 ± 0.3 | 2.8 ± 0.2 | −5 | 3.3 ± 0.2 | 3.2 ± 0.2 | −4 | 0.8 |
| Triglycerides (mmol/l) | 1.0 ± 0.1 | 0.8 ± 0.1 | −12 | 1.1 ± 0.2 | 1.3 ± 0.2 | +15 | 0.08 |
| BMI (kg/m2) | 36.3 ± 2.2 | 36.5 ± 2.2 | +0.5 | 38.9 ± 2.5 | 38.8 ± 2.5 | −0.3 | 0.5 |
Data are means ± SEM.
*
P < 0.05 for within-group analysis.
†
There was one outlier in the treatment group. With the exclusion of this subject, the change in FFA concentrations is a significant reduction of 46% (P = 0.02).